Background : Receptor status and molecular subtyping of breast cancers are crucial for patient management.We present here our initial experience on the status of different molecular subtypes and clinicopathological characteristics of invasive breast carcinomas in Bangladeshi population especially in Chittagong zone. Methods : A total of 59 histopathologically confirmed cases of invasive ductal carcinoma were selected for this study. Fifteen out of 59 cases were reported as HER2 equivalent and could not be categorized into any subtype because of the lack of availability of fluorescence in situ hybridization. The remaining 44 cases were distributed into different molecular subtypes and then the clinicopathological characteristics were compared for each molecular subtype. Results : Age ranges from 24-70 years with a mean age of 43.95 years. Most of the patients were in 41-50 years age group. Among the 44 cases, most common subtype was HER2/neu amplification 13 cases (29.55%). Luminal A, luminal B and basal like subtypes were 11 (25%) 10 (22.73%) and 10 (22.73%) respectively. The mean tumor size was 3.46 cm and the highest mean tumor size was in basal like subtype (4.01cm). Twenty five out of 59 cases (42.37%) showed axillary lymph node metastasis. Lowest axillary lymph node metastasis was found in luminal A subtype (3/11=27.27%). Conclusion : HER2/neu amplification subtype was found to be more common in this region. Luminal A subtype was found to be more favorable in comparison to the other subtypes in terms of axillary lymph node metastasis.
INTRODUCTION
Carcinoma of breast is the most common non-skin malignancy in women and is second only to lung cancer as acause of cancer deaths 1 . Variations in gene expression patterns in breast tumors have been identified by using complementary DNA microarray technology which defines several different molecular subtypes 2 . DNA microarray technology is very expensive and cannot be used on formalin-fixed, paraffin-embedded samples. Recent findings indicate that Immunohistochemical (IHC) protein expression profiles are surrogates for intrinsic genederived expression profiles defining molecular subtypes of breast cancer 3 . Molecular subtyping is crucial because these subtypes show striking differences with regard to patient characteristics, clinicopathological features,treatment response, and outcome 1 
RESULTS
The patients were from 24-70 years of age with a mean age of 43.95 years. Forty-one to fifty years age group represented most of the patients (25/59=42.37%) followed by 31-40 years (17/59=28.81%) 51-60 years (7/59=11.86%) 21-30 years (6/59=10.17%) and 61-70 years age groups (4/59=6.78%) [ Table 2 ].
Among the molecular subtypes, HER2/neu amplification subtype was the most common (13/44=29.55%) [ Figure 1 ]. Luminal A subtype was found mostly in 31-40 years age group (5/11=45.45%). Luminal B had 30% (3/10) cases in 31-40 years age group and also 30% (3/10) cases in 41-50 years age group. HER2/neu amplification and basal like subtypes were found mostly in 41-50 years age groups, 46.15% (6/13) and 60% (6/10) respectively.
The mean tumor size was 3.46 cm ranging from 1.4 cm to 9 cm in their largest dimension on gross examination. 10.17% tumors (6/59) were of less than 2 cm, 81.36% tumors (48/59) were in the range of 2-5 cm and 8.47% tumors (5/59) were more than 5 cm. All the tumors in basal like subtype (10/10) were more than 2 cm in size followed by luminal A subtype with 90.91% (10/11). Luminal B and HER2/neu amplification subtypes had 80% (8/10) and 76.92% (10/13) cases which were more than 2 cm in size. Among the molecular subtypes basal like was found to have the highest mean tumor size (4.01 cm) followed by HER2/neu amplification (3.67 cm), luminal A (3.05 cm) and luminal B subtypes (2.99 cm) [ Table 2 ].
Twenty five out of 59 cases (42.37%) showed axillary lymph node metastasis. Axillary lymph node metastasis in luminal A subtype was 27.27% (3/11). This was significantly lower than that of luminal B (40%=4/10), HER2/neu amplification (38.46%=5/13) and basal like subtypes (40%=4/10%) [ Table 2 ]. . However, Zhu et al found a mean age of 51 years in a similar study of 3198 cases in China. The lower mean age in our study population, Morocco and Pakistan than China can be explained by lower life expectancy in these countries compared with China. Moreover, Zhu et al worked on a larger sample size compared to others 12 .
Molecular subtypes Immunohistochemical characterization
In this study, HER2/neu amplification subtype was the most common subtype comprising 29.55% (13/44) of the total cases. Akbar et al found this subtype to be the most prevalent in their study in Pakistan (30%) as well 11 10, 12 . But in our study, luminal A subtype showed significantly lower incidence which is only 25% (11/44). This lower incidence of luminal A subtype in the present study may be partly due to less frequent use of menopausal hormone therapy and lack of mammographic screening program. But this demands further study to establish these factors as causes of lower incidence of luminal A subtype. Another possible reason may be that, since it is not a population based study rather a study on some selected case series, we may not get the exact scenario.
The mean tumor size in our study was 3.46 cm and 89.83% tumors were of more than 2 cm size in their largest dimension. Kumar et al from India also found similar results 13 . They reported mean tumor size 3.4 cm and 85.8% of their cases were having tumor size more than 2 cm. However, Zhu et al reported mean size of 2.1 cm 12 . The higher mean tumor size in our study and in India may be due to late consultation during the progression of the disease because of the existing social circumstances in this subcontinent. Another important cause may be the lack of mammographic screening program. All the basal like tumors (10/10) in this study were of more than 2 cm in size and the mean size of tumors was also highest in this subgroup (4.01 cm). This result corresponds with the result of Kumar et al where all the basal like tumors were of more than 2 cm size as well 13 .
Our study found lowest axillary lymph node metastasis rate in luminal A subtype (27.27%=3/11). Luminal B, HER2/neu amplification and basal like subtypes showed nearly equal lymph node metastasis rate. Kumar et al and El-Hawary et al in Egypt also found luminal A subtype to have the lowest rate of lymph node metastasis 13, 15 .
We could not categorize 15 out of 59 cases to any specific molecular subtype because of their IHC HER2 equivocal status. 
